Karyopharm Therapeutics (NASDAQ:KPTI) Share Price Crosses Above Fifty Day Moving Average – What’s Next?

Karyopharm Therapeutics Inc. (NASDAQ:KPTI)’s share price passed above its 50 day moving average during trading on Monday . The stock has a 50 day moving average of $6.24 and traded as high as $6.70. Karyopharm Therapeutics shares last traded at $6.47, with a volume of 248,256 shares trading hands.

Wall Street Analysts Forecast Growth

KPTI has been the subject of a number of analyst reports. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Karyopharm Therapeutics in a research report on Wednesday, October 8th. Robert W. Baird decreased their price objective on shares of Karyopharm Therapeutics from $25.00 to $21.00 and set an “outperform” rating for the company in a research report on Thursday, October 9th. HC Wainwright raised shares of Karyopharm Therapeutics from a “neutral” rating to a “buy” rating and set a $15.00 price objective for the company in a research report on Monday, October 13th. Finally, Piper Sandler reissued an “overweight” rating and issued a $12.00 price objective (down previously from $15.00) on shares of Karyopharm Therapeutics in a research report on Thursday, October 9th. Five equities research analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the stock. According to data from MarketBeat, the company has a consensus rating of “Moderate Buy” and a consensus price target of $18.20.

Karyopharm Therapeutics Trading Up 9.1%

The business’s 50 day moving average price is $6.24 and its 200-day moving average price is $5.25. The company has a market cap of $56.09 million, a price-to-earnings ratio of -0.44 and a beta of 0.34.

Karyopharm Therapeutics (NASDAQ:KPTI) last posted its earnings results on Monday, August 11th. The company reported ($4.32) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($3.80) by ($0.52). The firm had revenue of $37.93 million for the quarter, compared to the consensus estimate of $37.92 million. Karyopharm Therapeutics has set its FY 2025 guidance at EPS. Equities research analysts forecast that Karyopharm Therapeutics Inc. will post -0.71 EPS for the current fiscal year.

Institutional Trading of Karyopharm Therapeutics

A number of hedge funds have recently modified their holdings of KPTI. T. Rowe Price Investment Management Inc. acquired a new stake in shares of Karyopharm Therapeutics during the 1st quarter worth about $523,000. XTX Topco Ltd acquired a new stake in shares of Karyopharm Therapeutics during the 2nd quarter worth about $56,000. Silverback Asset Management LLC lifted its stake in shares of Karyopharm Therapeutics by 40.0% during the 2nd quarter. Silverback Asset Management LLC now owns 70,000 shares of the company’s stock worth $302,000 after buying an additional 20,000 shares during the last quarter. Baird Financial Group Inc. acquired a new stake in shares of Karyopharm Therapeutics during the 2nd quarter worth about $45,000. Finally, Bank of America Corp DE raised its stake in Karyopharm Therapeutics by 26.8% in the 2nd quarter. Bank of America Corp DE now owns 168,534 shares of the company’s stock worth $726,000 after purchasing an additional 35,626 shares in the last quarter. Institutional investors and hedge funds own 66.44% of the company’s stock.

Karyopharm Therapeutics Company Profile

Karyopharm Therapeutics Inc, a commercial-stage pharmaceutical company, discovers, develops, and commercializes drugs directed against nuclear export for the treatment of cancer and other diseases in the United States. The company discovers, develops, and commercializes novel and small molecule Selective Inhibitor of Nuclear Export (SINE) compounds that inhibit the nuclear export protein exportin 1 (XPO1).